| scholarly article | Q13442814 |
| P50 | author | Nathalie Sumien | Q59159287 |
| Ran Liu | Q41437484 | ||
| P2093 | author name string | Wenjun Li | |
| Shao-Hua Yang | |||
| James W Simpkins | |||
| Michael Forster | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| The ketogenic diet as a treatment paradigm for diverse neurological disorders | Q21129287 | ||
| Brain glycogen-new perspectives on its metabolic function and regulation at the subcellular level | Q21129443 | ||
| Mitochondrial Aβ A potential cause of metabolic dysfunction in Alzheimer's disease | Q22242986 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Frataxin interacts functionally with mitochondrial electron transport chain proteins | Q24305373 | ||
| Metabolism of ketonic acids in animal tissues | Q24535583 | ||
| Cerebral ischemia and Alzheimer's disease: the expression of amyloid-beta and apolipoprotein E in human hippocampus. | Q53390971 | ||
| Reduction in frataxin causes progressive accumulation of mitochondrial damage. | Q53649248 | ||
| AMPK is a direct adenylate charge-regulated protein kinase. | Q54580866 | ||
| AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. | Q54622561 | ||
| Glycogen: a Trojan horse for neurons | Q61774048 | ||
| Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine | Q64764588 | ||
| Glucose transporter localization in brain using light and electron immunocytochemistry | Q69522869 | ||
| Forebrain ischemia increases GLUT1 protein in brain microvessels and parenchyma | Q70808991 | ||
| Brain uptake and metabolism of [1-11C]octanoate in rats: pharmacokinetic basis for its application as a radiopharmaceutical for studying brain fatty acid metabolism | Q70818866 | ||
| Age-related changes in activities of mitochondrial electron transport complexes in various tissues of the mouse | Q73322830 | ||
| Hypoperfusion induces overexpression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model | Q73337645 | ||
| Characteristics of the in vitro vasoactivity of beta-amyloid peptides | Q74352860 | ||
| Some Patterns of the Respiratory Pigments of Ascites Tumors of Mice | Q81059939 | ||
| On getting there from here | Q82714730 | ||
| Lipid metabolism greases the stem cell engine | Q86086465 | ||
| Therapeutic strategies in Friedreich's ataxia | Q86598423 | ||
| Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. | Q34431008 | ||
| ATP citrate lyase is an important component of cell growth and transformation | Q34432794 | ||
| Higher transport and metabolism of glucose in astrocytes compared with neurons: a multiphoton study of hippocampal and cerebellar tissue slices | Q34435764 | ||
| Methylene blue as a cerebral metabolic and hemodynamic enhancer | Q34441680 | ||
| Metabolomic profiling reveals a role for CPT1c in neuronal oxidative metabolism | Q34457970 | ||
| A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury | Q34458328 | ||
| Topical 5-aminolevulinic acid and photodynamic therapy in dermatology: a minireview | Q34472690 | ||
| Mixed dementia: emerging concepts and therapeutic implications | Q34553430 | ||
| Molecular mechanisms of brain aging and neurodegenerative disorders: lessons from dietary restriction | Q34553820 | ||
| Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways | Q34583654 | ||
| Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics | Q34621634 | ||
| Co-enzyme Q10 and idebenone use in Friedreich's ataxia | Q34654338 | ||
| AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathies | Q34696305 | ||
| The coming acceleration of global population ageing | Q34737999 | ||
| Brain glucose transporter (Glut3) haploinsufficiency does not impair mouse brain glucose uptake. | Q34753989 | ||
| Neurodegeneration: what is it and where are we? | Q34828270 | ||
| Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses | Q34831241 | ||
| Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. | Q34963810 | ||
| The Critical Need to Promote Research of Aging and Aging-related Diseases to Improve Health and Longevity of the Elderly Population | Q35013326 | ||
| Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease | Q35130191 | ||
| Methylene blue | Q35170355 | ||
| Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation | Q35214038 | ||
| Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas | Q35533102 | ||
| Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models | Q35558517 | ||
| Methylene blue protects astrocytes against glucose oxygen deprivation by improving cellular respiration | Q35596204 | ||
| Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia | Q35653693 | ||
| Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. | Q35672405 | ||
| Coenzyme Q and vitamin E interactions | Q35707947 | ||
| Cancer metabolism: current perspectives and future directions | Q35723836 | ||
| Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough | Q35751844 | ||
| Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis | Q35789636 | ||
| Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal | Q35836597 | ||
| The Global Burden of Cancer 2013 | Q35847426 | ||
| Linking lipids to Alzheimer's disease: cholesterol and beyond | Q35875480 | ||
| Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders | Q24562763 | ||
| A new concept for energy coupling in oxidative phosphorylation based on a molecular explanation of the oxygen exchange reactions | Q24562919 | ||
| Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines | Q24598853 | ||
| Understanding the Warburg effect: the metabolic requirements of cell proliferation | Q24604760 | ||
| ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models | Q24628845 | ||
| AMPK in the brain: its roles in energy balance and neuroprotection | Q24629417 | ||
| Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity | Q24634209 | ||
| How mitochondria produce reactive oxygen species | Q24643882 | ||
| Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells | Q24655644 | ||
| Brick by brick: metabolism and tumor cell growth | Q24656187 | ||
| Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum | Q24657634 | ||
| Supply and demand in cerebral energy metabolism: the role of nutrient transporters | Q24671074 | ||
| Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts | Q24675729 | ||
| Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain | Q26825140 | ||
| Ageing as a risk factor for disease | Q26853545 | ||
| AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function | Q26865723 | ||
| Brain imaging in Alzheimer disease | Q26996299 | ||
| Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases | Q27009984 | ||
| Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease | Q27022757 | ||
| Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families | Q27860677 | ||
| The phosphoinositide 3-kinase pathway | Q27860738 | ||
| On the Origin of Cancer Cells | Q27861025 | ||
| Alzheimer's disease-do tauists and baptists finally shake hands? | Q28215968 | ||
| Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis | Q28218978 | ||
| Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke | Q28240112 | ||
| AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus | Q28254114 | ||
| Aetiology of Parkinson's disease | Q28261357 | ||
| Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited | Q28279921 | ||
| Energy metabolism in tumor cells | Q28288377 | ||
| Sequence and structure of a human glucose transporter | Q28305569 | ||
| Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature | Q28343882 | ||
| Mitochondrial targeted coenzyme Q, superoxide, and fuel selectivity in endothelial cells | Q28474562 | ||
| Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis | Q28477389 | ||
| Catalytic site cooperativity of beef heart mitochondrial F1 adenosine triphosphatase. Correlations of initial velocity, bound intermediate, and oxygen exchange measurements with an alternating three-site model | Q34055007 | ||
| The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. | Q34062645 | ||
| Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β. | Q34123865 | ||
| Phenothiazine: the seven lives of pharmacology's first lead structure | Q34159168 | ||
| Cholesterol metabolism in the brain | Q34193085 | ||
| Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. | Q34211659 | ||
| Experimental models of Parkinson's disease | Q34238077 | ||
| Calorie restriction and cancer prevention: a mechanistic perspective | Q34258945 | ||
| Updated energy budgets for neural computation in the neocortex and cerebellum | Q34262566 | ||
| Brain glucose transporters: relationship to local energy demand. | Q34272623 | ||
| Perfusion and metabolism imaging studies in Parkinson's disease. | Q34296504 | ||
| Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis | Q34296550 | ||
| A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease | Q34376103 | ||
| Aerobic glycolysis in the human brain is associated with development and neotenous gene expression | Q34397077 | ||
| Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 | Q34408888 | ||
| Oxygen glucose deprivation in rat hippocampal slice cultures results in alterations in carnitine homeostasis and mitochondrial dysfunction | Q34415826 | ||
| Cellular and molecular actions of Methylene Blue in the nervous system | Q34422385 | ||
| Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice | Q28484481 | ||
| Neuroprotective actions of methylene blue and its derivatives | Q28484659 | ||
| AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 | Q28506431 | ||
| Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system | Q28587570 | ||
| The biology of cancer: metabolic reprogramming fuels cell growth and proliferation | Q29547301 | ||
| A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine | Q29547303 | ||
| A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function | Q29547320 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 | ||
| Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 | ||
| The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics | Q29614972 | ||
| Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases | Q29615646 | ||
| Lipid rafts as a membrane-organizing principle | Q29615727 | ||
| The causes and consequences of genetic heterogeneity in cancer evolution | Q29615848 | ||
| An energy budget for signaling in the grey matter of the brain | Q29616192 | ||
| Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia | Q29616650 | ||
| AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism | Q29617261 | ||
| On respiratory impairment in cancer cells | Q29617276 | ||
| Otto Warburg's contributions to current concepts of cancer metabolism | Q29617601 | ||
| Metabolic reprogramming: a cancer hallmark even warburg did not anticipate | Q29617612 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy | Q29618101 | ||
| Neurovascular regulation in the normal brain and in Alzheimer's disease | Q29619659 | ||
| Coenzyme Q10 and α-tocopherol reversed age-associated functional impairments in mice. | Q30401821 | ||
| A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease | Q30433751 | ||
| Striatal neuroprotection with methylene blue | Q30479074 | ||
| N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking | Q30486372 | ||
| Astrocytic endfoot Ca2+ and BK channels determine both arteriolar dilation and constriction. | Q30493752 | ||
| Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. | Q30649677 | ||
| Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings | Q33253907 | ||
| Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. | Q33548817 | ||
| The neuropathology of probable Alzheimer disease and mild cognitive impairment | Q33616561 | ||
| Fatty acids in energy metabolism of the central nervous system | Q33634475 | ||
| AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. | Q33726605 | ||
| Cancer and neurodegeneration: between the devil and the deep blue sea. | Q33784620 | ||
| Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease | Q33789329 | ||
| Apolipoprotein E4: an allele associated with many diseases | Q33892393 | ||
| Lipid raft microdomains and neurotransmitter signalling | Q34001685 | ||
| Astrocyte-neuron metabolic relationships: for better and for worse | Q34025337 | ||
| Astrocyte-neuron lactate transport is required for long-term memory formation | Q34025968 | ||
| Expression and distribution of beta amyloid precursor protein and beta amyloid peptide in reactive astrocytes after transient middle cerebral artery occlusion. | Q53243101 | ||
| The metabolic syndrome and Alzheimer disease. | Q53284115 | ||
| Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. | Q53301872 | ||
| Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first? | Q37294059 | ||
| Is cancer a disease of abnormal cellular metabolism? New angles on an old idea | Q37305385 | ||
| Mitochondrial fatty acid synthesis type II: more than just fatty acids | Q37333233 | ||
| (ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease | Q37357084 | ||
| Mitochondrial dynamics and cancer. | Q37367020 | ||
| Tumor suppressors and cell metabolism: a recipe for cancer growth | Q37390879 | ||
| AMP-activated protein kinase--a sensor of glycogen as well as AMP and ATP? | Q37401922 | ||
| Lymph node staging in colorectal cancer: old controversies and recent advances | Q37408817 | ||
| Friedreich ataxia: the clinical picture | Q37414025 | ||
| AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. | Q37440366 | ||
| What learning in day-old chickens can teach a neurochemist: focus on astrocyte metabolism | Q37459040 | ||
| Direct measurement of oxidative metabolism in the living brain by microdialysis: a review | Q37459046 | ||
| Mitochondria impact brain function and cognition. | Q37475044 | ||
| Methylene blue and Alzheimer's disease. | Q37477451 | ||
| Mitochondria in Huntington's disease | Q37580111 | ||
| Extinction memory improvement by the metabolic enhancer methylene blue | Q37583001 | ||
| Is there a primary role of the mitochondrial genome in Alzheimer's disease? | Q37607115 | ||
| Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research | Q37647283 | ||
| The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives | Q37656554 | ||
| Parkinson's disease and cancer risk: a systematic review and meta-analysis | Q37669823 | ||
| Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease | Q37671390 | ||
| The use of PET in Alzheimer disease | Q37688880 | ||
| Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans. | Q37691575 | ||
| Direct evidence for activity-dependent glucose phosphorylation in neurons with implications for the astrocyte-to-neuron lactate shuttle. | Q37701970 | ||
| Mitochondria dysfunction and neurodegenerative disorders: cause or consequence | Q37750253 | ||
| Behavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue | Q37750487 | ||
| Lipids in Alzheimer's disease: A century-old story | Q37752946 | ||
| Metabolism strikes back: metabolic flux regulates cell signaling | Q37821147 | ||
| "Lest we forget you--methylene blue...". | Q37840811 | ||
| Why does the brain (not) have glycogen? | Q37845323 | ||
| AMP-activated protein kinase: a potential player in Alzheimer's disease | Q37881988 | ||
| Anticancer drugs targeting the mitochondrial electron transport chain | Q37903332 | ||
| Targeting cancer metabolism: a therapeutic window opens | Q37924094 | ||
| Role of astrocytes in neurovascular coupling. | Q37929350 | ||
| Therapeutic targeting of Myc-reprogrammed cancer cell metabolism | Q37940934 | ||
| Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. | Q37954003 | ||
| Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation | Q37966074 | ||
| Targeting cancer metabolism--aiming at a tumour's sweet-spot | Q37972239 | ||
| Sporadic Alzheimer's disease: the starving brain | Q38008784 | ||
| Mitochondrial respiratory chain dysfunction: implications in neurodegeneration. | Q38010826 | ||
| Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system | Q38093006 | ||
| Mitochondrial pathophysiology in Friedreich's ataxia | Q38121943 | ||
| The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator | Q38184207 | ||
| Lipid metabolism in Alzheimer's disease | Q38204719 | ||
| The involvement of lipids in Alzheimer's disease. | Q38217401 | ||
| Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications | Q38232472 | ||
| Huntington's disease: an update of therapeutic strategies | Q38275248 | ||
| Cerebral glycolysis: a century of persistent misunderstanding and misconception | Q38283519 | ||
| Mitochondria as biosynthetic factories for cancer proliferation. | Q38332527 | ||
| The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. | Q38357762 | ||
| The Parkinson Disease Mitochondrial Hypothesis: Where Are We at? | Q38374332 | ||
| AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation | Q39086948 | ||
| Effect of DHA and coenzymeQ10 against Aβ- and zinc-induced mitochondrial dysfunction in human neuronal cells | Q39110694 | ||
| Multifunctional role of astrocytes as gatekeepers of neuronal energy supply | Q39734463 | ||
| AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q39776724 | ||
| Acute activation of glucose uptake by glucose deprivation in L929 fibroblast cells | Q40225772 | ||
| Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 | ||
| THE CONTROL OF METHEMOGLOBINEMIA WITH METHYLENE BLUE. | Q40971873 | ||
| THE NITROUS OXIDE METHOD FOR THE QUANTITATIVE DETERMINATION OF CEREBRAL BLOOD FLOW IN MAN: THEORY, PROCEDURE AND NORMAL VALUES. | Q40998839 | ||
| A phenothiazine derivative reduces rat brain damage after global or focal ischemia | Q41110498 | ||
| Mitochondrial complex I deficiency in Parkinson's disease | Q41821730 | ||
| STUDIES ON BLOOD CELL METABOLISM : I. THE EFFECT OF METHYLENE BLUE AND OTHER DYES UPON THE OXYGEN CONSUMPTION OF MAMMALIAN AND AVIAN ERYTHROCYTES | Q41877539 | ||
| A mouse model for Glut-1 haploinsufficiency. | Q41919807 | ||
| Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. | Q42077623 | ||
| Signaling in control of cell growth and metabolism | Q42219207 | ||
| The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction | Q42471480 | ||
| Methylene blue stimulates 2-deoxyglucose uptake in L929 fibroblast cells | Q42483139 | ||
| Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy | Q42554136 | ||
| Methylene blue for ifosfamide-associated encephalopathy | Q42565781 | ||
| Chemical manipulation of hsp70 ATPase activity regulates tau stability. | Q42630080 | ||
| Sugar and Alzheimer's disease: a bittersweet truth | Q42698401 | ||
| THE CATALYTIC EFFECT OF METHYLENE BLUE ON THE OXYGEN CONSUMPTION OF TUMORS AND NORMAL TISSUES. | Q42794099 | ||
| Phenothiazines interfere with dopaminergic neurodegeneration in Caenorhabditis elegans models of Parkinson's disease | Q43093424 | ||
| Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish | Q43104150 | ||
| AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation | Q43772807 | ||
| Toward the neurovascular unit. A journey in clinical translation: 2012 Thomas Willis Lecture | Q44310641 | ||
| Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease | Q44418055 | ||
| Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy | Q35882137 | ||
| It's a lipid's world: bioactive lipid metabolism and signaling in neural stem cell differentiation | Q35931476 | ||
| Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity | Q35985945 | ||
| A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer | Q36048908 | ||
| Sweet sixteen for ANLS. | Q36079324 | ||
| Monocarboxylate transporters in the central nervous system: distribution, regulation and function. | Q36161586 | ||
| Friedreich's ataxia is a mitochondrial disorder | Q36173065 | ||
| Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease | Q36343094 | ||
| Cholesterol: its regulation and role in central nervous system disorders | Q36355194 | ||
| Deleterious effects of neuronal accumulation of glycogen in flies and mice | Q36386453 | ||
| Expanding insights of mitochondrial dysfunction in Parkinson's disease. | Q36404133 | ||
| Cloning and characterization of a cDNA encoding the rat brain glucose-transporter protein | Q36425439 | ||
| AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer | Q36448932 | ||
| The role of mitochondria in ageing and carcinogenesis | Q36484983 | ||
| GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration | Q36526013 | ||
| AMP-activated protein kinase signaling in metabolic regulation | Q36528537 | ||
| Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models | Q36538885 | ||
| The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease | Q36611426 | ||
| The role of mitochondria in aging | Q36638140 | ||
| Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis | Q36653551 | ||
| Mechanisms of Disease: astrocytes in neurodegenerative disease | Q36658874 | ||
| Reversing the Warburg effect as a treatment for glioblastoma | Q36725003 | ||
| Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia | Q36775208 | ||
| Methylene blue induces macroautophagy through 5' adenosine monophosphate-activated protein kinase pathway to protect neurons from serum deprivation | Q36812658 | ||
| Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study | Q36825067 | ||
| Coenzyme Q10: is there a clinical role and a case for measurement? | Q36869671 | ||
| Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids | Q36895786 | ||
| Oxidative stress and neurotoxicity | Q37021184 | ||
| Role of Lipids in Brain Injury and Diseases | Q37051065 | ||
| Neurovascular signalling defects in neurodegeneration | Q37078102 | ||
| A dietary regimen of caloric restriction or pharmacological activation of SIRT1 to delay the onset of neurodegeneration | Q37178403 | ||
| Cerebral amyloid angiopathy: progressive disruption of the neurovascular unit | Q37186592 | ||
| Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells | Q37189912 | ||
| The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation | Q37200468 | ||
| Reduction and uptake of methylene blue by human erythrocytes | Q44770026 | ||
| Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats | Q44776053 | ||
| Binding, aggregation and photochemical properties of methylene blue in mitochondrial suspensions. | Q44871471 | ||
| Increased beta-secretase activity and expression in rats following transient cerebral ischemia | Q44878523 | ||
| Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease | Q44918546 | ||
| Potential role for AMP-activated protein kinase in hypoglycemia sensing in the ventromedial hypothalamus | Q44995520 | ||
| Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein | Q45048594 | ||
| The metabolic syndrome, inflammation, and risk of cognitive decline | Q45145786 | ||
| Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. | Q45305438 | ||
| Methylene blue provides behavioral and metabolic neuroprotection against optic neuropathy | Q46041449 | ||
| Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. | Q46149691 | ||
| Triiodothyronine (T3) stimulates food intake via enhanced hypothalamic AMP-activated kinase activity | Q46425970 | ||
| Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. | Q46495742 | ||
| Glucocorticoids increase neuropeptide Y and agouti-related peptide gene expression via adenosine monophosphate-activated protein kinase signaling in the arcuate nucleus of rats | Q46555406 | ||
| Glucose transport in primary cultured neurons | Q46903557 | ||
| Methylene blue prevents neurodegeneration caused by rotenone in the retina. | Q46932990 | ||
| Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. | Q46938722 | ||
| Methylene blue rescues heart defects in a Drosophila model of Friedreich's ataxia. | Q47072694 | ||
| Hope in Alzheimer's fight emerges from unexpected places | Q47562983 | ||
| New hope from an old drug: fighting Alzheimer's disease with the cancer drug bexarotene (targretin)? | Q47621322 | ||
| Why does methylene blue reduce methemoglobin in benzocaine poisoning but beneficially oxidize hemoglobin in cyanide poisoning? | Q47783416 | ||
| Methylene blue improves brain oxidative metabolism and memory retention in rats | Q48094476 | ||
| Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake | Q48111745 | ||
| Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue | Q48154783 | ||
| Paul Ehrlich: founder of chemotherapy | Q48322871 | ||
| Human brain glycogen content and metabolism: implications on its role in brain energy metabolism | Q48355244 | ||
| L-carnitine protects neurons from 1-methyl-4-phenylpyridinium-induced neuronal apoptosis in rat forebrain culture | Q48379062 | ||
| Energy-efficient action potentials in hippocampal mossy fibers | Q48462235 | ||
| Phenothiazines as lipid peroxidation inhibitors and cytoprotective agents | Q48526674 | ||
| GLUT-1 expression in the cerebra of patients with Alzheimer's disease | Q48589517 | ||
| Structural and functional aspects of the respiratory chain of synaptic and nonsynaptic mitochondria derived from selected brain regions | Q48765883 | ||
| Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. | Q48953365 | ||
| The amyloid cascade hypothesis | Q49075559 | ||
| Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a development, with special reference to the influence of Paul Ehrlich. | Q49145255 | ||
| Methylene blue protects primary rat retinal ganglion cells from cellular senescence | Q50246048 | ||
| Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models | Q50260881 | ||
| Drugs: a tangled web of targets | Q50436787 | ||
| Methylene blue injection into the rectal artery as a simple method to improve lymph node harvest in rectal cancer. | Q50469230 | ||
| Use of methylene blue as a diagnostic aid in early detection of oral cancer and precancerous lesions. | Q50474498 | ||
| AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease. | Q50489380 | ||
| Pharmacokinetics and organ distribution of intravenous and oral methylene blue. | Q50509915 | ||
| Parkinson's disease: a model dilemma. | Q50671543 | ||
| Selective surface staining of bladder tumors by intravesical methylene blue with enhanced endoscopic identification | Q50921974 | ||
| In vivo mapping of bladder cancer (chromocystoscopy for in vivo detection of neoplastic urothelial surfaces). | Q50922882 | ||
| In vivo staining test with methylene blue for bladder cancer. | Q50927998 | ||
| The theoretical basis of Paul Ehrlich's chemotherapy. | Q50941029 | ||
| The acceptor specificity of flavins and flavoproteins. II. Free flavins. | Q50971085 | ||
| The utility of superoxide dismutase in studying free radical reactions. II. The mechanism of the mediation of cytochrome c reduction by a variety of electron carriers. | Q50973229 | ||
| THE ACTION OF GRAMICIDIN D ON ISOLATED LIVER MITOCHONDRIA. | Q50983150 | ||
| Astrocytes: powering memory. | Q51017940 | ||
| Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. | Q53196303 | ||
| P921 | main subject | neurodegeneration | Q1755122 |
| P304 | page(s) | 273-291 | |
| P577 | publication date | 2015-11-18 | |
| P1433 | published in | Progress in Neurobiology | Q15716615 |
| P1476 | title | Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots | |
| P478 | volume | 157 |
| Q48274386 | Combination Treatment with Methylene Blue and Hypothermia in Global Cerebral Ischemia |
| Q60957181 | Combined In Vitro Studies and in Silico Target Fishing for the Evaluation of the Biological Activities of and |
| Q91987516 | Combining lipoic acid to methylene blue reduces the Warburg effect in CHO cells: From TCA cycle activation to enhancing monoclonal antibody production |
| Q48004149 | From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue. |
| Q64928897 | Inhibiting the NLRP3 Inflammasome With Methylene Blue as Treatment Adjunct in Myelodysplasia. |
| Q39199926 | Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism. |
| Q46248197 | Methylene Blue Protects the Isolated Rat Lungs from Ischemia-Reperfusion Injury by Attenuating Mitochondrial Oxidative Damage. |
| Q97524144 | Methylene blue ameliorates brain edema in rats with experimental ischemic stroke via inhibiting aquaporin 4 expression |
| Q46279374 | New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells |
| Q49982031 | TGF-b1 or Hypoxia Enhance Glucose Metabolism and Lactate Production via HIF1A Signaling in Tendon Cells. |
| Q52343842 | Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms. |
Search more.